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Abstract Genome-wide association studies have found variation within the complement factor  
H gene family links to host susceptibility to meningococcal disease caused by infection with 
Neisseria meningitidis (Davila et al., 2010). Mechanistic insights have been challenging since 
variation within this locus is complex and biological roles of the factor H-related proteins, unlike 
factor H, are incompletely understood. N. meningitidis subverts immune responses by hijacking  
a host-immune regulator, complement factor H (CFH), to the bacterial surface (Schneider et al., 
2006; Madico et al., 2007; Schneider et al., 2009). We demonstrate that complement factor-H 
related 3 (CFHR3) promotes immune activation by acting as an antagonist of CFH. Conserved 
sequences between CFH and CFHR3 mean that the bacterium cannot sufficiently distinguish 
between these two serum proteins to allow it to hijack the regulator alone. The level of protection 
from complement attack achieved by circulating N. meningitidis therefore depends on the relative 
levels of CFH and CFHR3 in serum. These data may explain the association between genetic 
variation in both CFH and CFHR3 and susceptibility to meningococcal disease.
DOI: 10.7554/eLife.04008.001
Introduction
Neisseria meningitidis is an important cause of rapidly progressive septicaemia and meningitis in 
children and young adults (Stephens et al., 2007); case fatality rates for bacteraemic disease remain 
at around 10%, and a significant proportion of survivors are left with long-term sequelae (Vyse et al., 
2013). For most individuals, however, this human-specific bacterium is primarily a non-pathogenic 
commensal of the nasopharynx, and up to 40% of the population are healthy carriers (Caugant and 
Maiden, 2009). The mechanisms underlying human genetic influences that govern the development 
of invasive disease or asymptomatic carriage are incompletely understood. It is known, however, that 
complement activation is critical for protection against disease, evident from the susceptibility of indi-
viduals with genetic deficiency of either the alternative complement pathway (AP) or terminal pathway 
activation, and among those receiving therapy that prevents terminal pathway activation (Schneider 
et al., 2007; McKeage, 2011). Amongst several strategies that promote complement evasion, 
N. meningitidis recruits the human negative complement regulator, complement factor H (CFH), to its 
surface by expressing factor H binding protein (fHbp) (Schneider et al., 2006, 2009; Madico et al., 
2007). fHbp can be divided into three variant groups (V1, V2, and V3), which have >85% sequence 
identity within the groups but only 60–70% similarity between groups (Masignani et al., 2003; 
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Brehony et al., 2009). fHbps from all variant groups bind CFH with a KD in the low nanomolar range 
(Johnson et al., 2012). Therefore, it is significant that the only single nucleotide polymorphisms (SNPs) 
associated with meningococcal disease in a recent genome-wide association study (GWAS) were those 
among the CFH–CFHR locus. These included SNPs within CFH and the downstream gene, CFHR3 
(Davila et al., 2010). While CFH has been extensively studied (reviewed in Makou et al. (2013)), the 
role of the serum protein CFHR3 has not been unambiguously established (reviewed in Jozsi and 
Meri (2014)).
Results and discussion
We recently demonstrated that three of the five CFHR proteins (i.e., CFHR1, 2, and 5) compete with 
CFH for binding to C3b on heterologous erythrocytes, thereby promoting complement activation 
(Goicoechea de Jorge et al., 2013). Given the association of CFHR3 with meningococcal disease 
(Davila et al., 2010), we investigated whether this protein and CFHR4 also act as CFH antagonists in 
this assay. We generated full-length CFHR3 and CFHR4B (which both consist of five complement con-
trol protein [CCP] domains, Figure 1A) and truncated versions of these proteins, and we examined 
their ability to influence complement activation by the AP, which is regulated by CFH (Makou et al., 
2013). Erythrocyte haemolysis assays demonstrate that CFHR3 and CFHR4B are also CFH antagonists 
on this surface, with their two C-terminal domains enabling them to compete with CFH for binding 
sites on cell complement fragments such as C3b (Figure 1B, Figure 1—figure supplement 1A,B). 
Additional cell-surface recognition sites within other domains (Figure 1A) increase the activity of the 
full-length CFHR3 and CFHR4B as competitive antagonists of CFH (Figure 1B) at physiologically rele-
vant concentrations of ∼1 μM (Fritsche et al., 2010; Hebecker and Jozsi, 2012).
eLife digest Meningitis is a potentially life-threatening condition whereby the membranes that 
cover and protect the brain and spinal cord become inflamed. Often meningitis is caused by a viral 
or bacterial infection—such as infection by a bacterium called Neisseria meningitidis, also known as 
meningococcus. However, not everyone that comes into contact with this bacterium will develop 
meningitis; 40% of the population is thought to carry N. meningitidis at the back of the nasal cavity 
and yet show no signs of the disease.
It remains unclear why some people exposed to N. meningitidis develop meningitis while others 
do not; however recent research revealed that part of the immune system called the complement 
system plays a role in susceptibility to meningitis. The complement system is a collection of small 
proteins that work together to support the actions of the cells of the immune system. When 
activated, complement proteins trigger a cascade of events that helps to destroy the pathogen.
Several mechanisms exist to keep the complement proteins in check—for example, a protein 
called complement factor H (or CFH) protects host cells from being attacked by other complement 
proteins. N. meningitidis can undermine the complement system by expressing a protein that binds 
to CFH and firmly fixes CFH to its cell surface. While the CFH-binding protein helps explain why 
some people are unable to mount the appropriate immune response to infection by N. meningitidis, 
it does not explain why some carriers of the pathogen do not develop meningitis.
Now, Caesar et al. have examined a protein called CFH related-3 (or CFHR3), and discovered 
that CFHR3 competes with CFH for the binding protein on N. meningitidis. CFHR3 is structurally 
similar to CFH, but it is unable to regulate or silence the complement system. Caesar et al. explain 
that susceptibility to meningococcal disease is determined by how much CFH and how much CFHR3 
each individual has, and that those with less CFHR3 will be more susceptible to N. meningitidis. 
An individual's genes will affect how much CFH and CFHR3 they have, while the genes of the 
bacterium can influence how strongly the CFH binding protein binds to either of these human 
proteins. Caesar et al. suggest that these two factors determine whether or not an individual will 
develop meningitis or simply carry the bacterium without any ill effects.
Caesar et al.'s findings highlight the different ways that people's genes can determine how they 
respond to an invading pathogen. The findings also suggest that it is important to consider variation 
in the levels of these complement proteins across a population when planning immunisation schedules.
DOI: 10.7554/eLife.04008.002
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N. meningitidis fHbp recruits CFH by high-affinity interactions primarily with domain 6 of CFH 
(CFH6) with some limited contact to CFH7 (Schneider et al., 2009). Since the first domains of the CFHRs 
share between 40% to 90% identity with CFH6 (Figure 1A, Figure 2), we next investigated whether 
fHbp also bound the CFHRs. Our findings (Figure 1C) demonstrate that CFHR3 binds fHbp with a KD 
of ∼3 nM, similar to affinities for CFH (Schneider et al., 2009; Johnson et al., 2012); no significant 
binding was detected for the other CFHRs with fHbp. Of note, the first two domains of CFHR3 
(CFHR312; domain 1 shares 91% identity with CFH6, Figure 1A) and the full-length protein bind fHbp 
with similar affinities (Figure 1E, Figure 1—figure supplement 1C,D). Furthermore, a point mutation 
within fHbp (E255A) that reduces binding to CFH by more than three orders of magnitude (Johnson 
et al., 2012) similarly reduces CFHR3 binding (Figure 1E). The nature of the CFH and CFHR3 interac-
tions with fHbp are therefore similar, with these complement factors occupying overlapping sites on 
fHbp, which is consistent with the high degree of conservation of their fHbp binding sites (Figure 2).
Next we investigated whether CFHR3 binds to the surface of N. meningitidis. We generated a 
CFHR3-specific monoclonal antibody (mAb) (Figure 3—figure supplement 1), designated HSL1. By 
flow cytometry we demonstrated that serum CFHR3 bound N. meningitidis M1239 (which expresses 
V3.28 fHbp) in a fHbp-dependent manner. No binding was detected following incubation of bacteria 
in sera from an individual homozygous for an allele in which there is combined deletion of the 
CFHR1 and CFHR3 genes (ΔCFHR3/1) (ΔCFHR3/1, Figure 3A,B,C). We therefore tested the functional 
consequences of CFHR3 binding by comparing the effect of adding full length or domains of CFHR3 
Figure 1. CFHR3 binds N. meningitidis fHbp at the same site as CFH and promotes complement activation. (A) Complement control protein (CCP) 
domains of CFH, CFHR3, and CFHR4 are shown with the sequence identity to CFH and between the CFHRs indicated. Key functional regions of CFH  
are noted. (B) CFH-dependent alternative pathway (AP) haemolytic assay (Goicoechea de Jorge et al., 2013). Using a CFH dose that reduced lysis of 
guinea pig erythrocytes to 50%, the addition of increasing concentrations of either full-length or C-terminal fragments of CFHR3 or CFHR4 resulted in a 
dose-dependent increase in lysis. The two N-terminal CCP domains from CFHR3 had no effect (not shown). (C) Surface plasmon resonance (SPR) was 
used to investigate interactions of CFHRs with fHbp. Full-length and fragments of CFH and CFHRs were injected (black bar) over surface bound fHbp3.28. 
Only CFHR312, full-length CFHR3, or CFH67 bind to fHbp. (D) Dissociation constants (KD) measured by SPR (CFHR312) or microscale thermophoresis 
(CFHR3) indicated the fHbp binding site is within the two N-terminal domains of CFHR3. (E) SPR with 200 nM protein flowing over V3.28 fHbp demon-
strates that the single point mutation E255A, which ablates CFH binding, also ablates CFHR12 binding.
DOI: 10.7554/eLife.04008.003
The following figure supplement is available for figure 1:
Figure supplement 1. Increased haemolysis on addition of CFHR3 is dependent on presence of CFH and interaction of CFHR3 full length and 
N-terminal fragment with V3.28 fHbp. 
DOI: 10.7554/eLife.04008.004
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to N. meningitidis prior to incubation in normal human serum (NHS). Addition of full-length CFHR3 
or CFHR312, which contains the fHbp binding site (Figure 1C) but has no CFH antagonist activity 
(Figure 1B), resulted in significantly reduced bacterial survival (CFHR3 51%; CFHR312 70%; no protein 
or CFHR345 83%, Figure 3D); in contrast, CFHR3 had no detectable effect in the presence of heat-
inactivated NHS (which lacks complement activity, Figure 3D). Full-length CFHR3 has a more marked 
effect on bacterial survival than CFHR312, consistent with the ability of the full-length CHHR3 to bind 
to C3b deposited on the bacterial surface (via CFHR345) as well as competing with CFH for fHbp (via 
CFHR312). As CFHR345 does not bind fHbp (Figure 1C), its CFH antagonist activity is not effectively 
localized to the meningococcal surface, providing an explanation for why these domains have no 
effect on bacterial survival (Figure 3D). Similarly, addition of CFHR3 has no effect on serum survival 
of bacteria that do not express any CFH-binding protein (Figure 3—figure supplement 2A, 
N. meningitidis strain lacking fHbp expression; Figure 3—figure supplement 2B, Escherichia coli 
strain with no expression of any CFH-binding protein).
Figure 2. Amino acid differences between CFHR3 and CFH in the fHbp binding site. (A) Sequence alignment 
between CFHR312 and CFH67. Differences are highlighted in red text, the two differences within the fHbp binding 
site are highlighted in yellow and residues contacting fHbp in the CFH-fHbpV3 structure (PDB ID 4AYM [Johnson 
et al., 2012]), chains A and D are indicated by an asterisk below the CFH sequence. (B) CFH67 is shown as a grey 
surface with residues that differ in CFHR3 highlighted in red; fHbp is shown as a green ribbon. (C) Rotated 90° 
around x compared to the view in B. (D) Looking down onto the fHbp binding site on CFH the two, conservative, 
sequence differences between the CFH67 and CFHR312 found in the binding site are indicated in red on the  
grey surface.
DOI: 10.7554/eLife.04008.005
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The finding that CFHR3 binding impairs bacterial survival in NHS led us to consider whether fHbp 
can distinguish between the limited sequence differences between CFH and CFHR3 to generate 
specificity for CFH. We previously identified a series of alanine substitutions in fHbp that significantly 
reduce or ablate CFH binding (Johnson et al., 2012). Therefore, we measured the contribution of 
fHbp residues to interactions with CFHR3 to determine whether any amino acid changes altered the 
specificity of fHbp for the two complement factors (Figure 4A, Figure 4—source data 1). The results 
demonstrate that the majority of mutations that impair CFH binding (Johnson et al., 2012) also 
significantly reduce CFHR3 binding, so do not alter specificity for CFH; point mutations at only a few 
sites led to modest alterations in specificity at levels that are unlikely to be physiologically relevant 
given the relative affinities for CFHR3/CFH and their abundance in serum (CFHR3 1–1.6 μM [Fritsche 
et al., 2010; Hebecker and Jozsi, 2012]; CFH 1–4 μM [Hakobyan et al., 2008]). Interestingly the V1 
fHbp used as the background for the mutations (V1.1) did reveal a degree of specificity for CFH over 
Figure 3. N. meningitidis binds CFHR3 on its surface in an fHbp-dependent manner promoting complement- 
mediated lysis. (A–C) Flow cytometry of N. meningitidis demonstrates that CFHR3 binds to fHbp on the bacterial 
surface. (D) Sensitivity of N. meningitidis strain M1239 to complement-mediated cell lysis after pre-incubation 
with 1 µM CFHR3, CFHR312, CFHR345, or no protein. Faded symbols are bacteria incubated in identical conditions 
except using heat-inactivated NHS instead of NHS. Data presented as percentage survival relative to bacteria 
incubated in heat-inactivated NHS without additional CFHR3. Line shows the mean of three independent biologi-
cal experiments, each with three technical replicates; individual results indicated. Significance was calculated using 
a two-tailed unpaired t test comparing with values obtained with no additional protein: ****p < 0.0001; *p < 0.05; 
ns p > 0.05.
DOI: 10.7554/eLife.04008.006
The following figure supplements are available for figure 3:
Figure supplement 1. Characterisation of the novel anti-CFHR3 antibody HSL1. 
DOI: 10.7554/eLife.04008.007
Figure supplement 2. The effect of CFHR312 on bacterial survival is dose and fHbp dependent. 
DOI: 10.7554/eLife.04008.008
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CFHR3 (in the order of ∼20-fold) in contrast to V2 and V3 fHbps, suggesting that certain fHbps can 
discriminate between CFH and CFHR3.
To investigate this further, we measured binding of CFH and CFHR3 to 25 naturally occurring 
fHbps that are prevalent in disease isolates of N. meningitidis (Figure 4B, Figure 4—source data 1) 
(Lucidarme et al., 2009). This demonstrated that V2 and V3 fHbps displayed no selective affinity for 
CFH over CFHR3 (average selectivity being 1.8 ± 1.4 and 2.4 ± 1.0, respectively). In contrast, V1 fHbps 
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Figure 4. Key residues in fHbp that mediate binding to CFHR3. (A) SPR was used to determine KDs for both CFH67 
and CFHR312 binding to a panel of fHbps bearing alanine substitutions within the CFH67 binding site. ∼50 mutations 
were screened in each of three fHbps (V1.1, 2.21 and 3.28 [Johnson et al., 2012]). Mutations altered KDs for both 
CFH67 and CFHR312 but some mutations led to some specificity for binding one or the other protein (see full data  
in Extended Data File 1). (B) KDs were determined for a panel of fHbps from disease causing N. meningitidis.  
V1 fHbps have some ability to preferentially bind CFH67 vs CFHR312, whilst V2 and V3 fHbps were less able to 
distinguish the molecules (full data in Extended Data File 2). (C) AP-mediated bacterial killing of isogenic strains 
expressing different fHbps in the presence of CFHR3. Data are coloured as in panel (B) and bacterial survival in 
serum is increased in the strain expressing the fHbpV1.1 (that has the maximal specificity for CFH vs CFHR3).
DOI: 10.7554/eLife.04008.009
The following source data is available for figure 4:
Source data 1. Excel spreadsheet with full details of KDs for CFH and CFHR312 derived from 1:1 Langmuir fits of 
SPR data for alanine scanning mutants and natural variant fHbp sequences. 
DOI: 10.7554/eLife.04008.010
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had lower affinities for CFHR3 compared to CFH (average selectivity 8.9 ± 4.6-fold), with 12 of the 
14 V1 fHbp variants binding CFH 5- to 20-fold more tightly than CFHR3. Modeling the effect on 
the occupancy of fHbp with CFH indicates that certain V1 fHbps will be bound by CFH in the physio-
logical situation regardless of CFHR3 levels (Figure 5). To examine whether this has any functional 
consequence, we examined complement AP killing of isogenic strains expressing fHbp sequences 
with different abilities to discriminate between CFH and CFHR3 (Figure 4C); AP killing was assessed 
to exclude any confounding influence of antibodies in sera preferentially recognizing different fHbps. 
Bacteria expressing V3.28 fHbp, which has identical affinities for CFH and CFHR3, were the most sen-
sitive to AP killing, while the strain expressing the V1.1 fHbp sequence (which has ∼20-fold tighter 
binding to CFH than CFHR3) was the least sensitive; bacteria with fHbps with intermediate CFH 
specificity displayed intermediate levels of protection. This suggests that, even though the most 
specific fHbps bind CFHR3 with a KD significantly below the physiological concentration (Figure 4—
source data 1), the ability of fHbp to favour CFH binding promotes bacterial survival and offers 
a potential explanation for the prevalence of strains expressing V1 fHbp causing invasive disease 
(Lucidarme et al., 2009).
To define the basis for the effect of CFHR3 on bacterial survival, we next examined the impact of 
CFHR3 on levels of CFH bound to the bacterial surface. N. meningitidis incubated in the ΔCFHR3/1 
sera acquire high levels of CFH on the bacterial surface (Figure 6A,B,C). However, addition of 
Figure 5. Modelling the occupancy of bacterial cell surface fHbp assuming different levels of specificity for  
CFH over CFHR3. Each molecule of fHbp on the bacterial surface can bind with one molecule of CFHR3 or one 
molecule of CFH. Assuming that the number of molecules of either of these is significantly greater than the number 
of molecules of fHbp then the percentage of bacterial surface fHbp molecules binding CFH at equilibrium will be 
determined by: the relative amounts of both present in the individual; and the affinities of that fHbp sequence for 
CFH vs CFHR3 (essentially a model of competitive antagonism, see equation below). Natural fHbp sequences are 
relatively constant in their KD for CFH (KD ∼3 nM [Johnson et al., 2012] and this work), therefore we modelled the 
effect of the KD for CFHR3 varying between 3 nM and 300 nM against this constant KD for CFH under two condi-
tions. In red we assume that both CFH and CFHR3 are present in serum at 1.5 μM, whilst in blue we model the 
effect if the concentration of CFH is twice that of CFHR3 (i.e., 3 μM vs 1.5 μM). This range of relative concentrations 
covers those generally reported for CFH and CFHR3 (except in the case of ΔCFHR3/1 individuals where the 
concentration of CFHR3 will be zero and 100% of the fHbp will bind CFH). The grey shaded areas indicate the 
regions of the x axis into which the families of natural variant fHbp sequences studied in Figure 3 fall. The equation 
used to generate these curves is:
[ ]
( )
 = *100.
[ ] [ 3]
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( ) ( 3)
D
D D
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DOI: 10.7554/eLife.04008.011
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Figure 6. Susceptibility to N. meningitidis will be altered by the circulating levels of CFH and CFHR3 that compete for binding to fHbp. (A–C) Flow 
cytometry demonstrates that addition of increasing amounts of CFHR3 (from 0 μM [light blue] to 1 μM [black]) to sera from a ΔCFHR3–1 individual leads 
to decreasing levels of CFH on the bacterial surface (A and C) and increasing levels of CFHR3 (B and C). (D) Model of how differing levels of CFHR3 and 
CFH in an individual combine to alter the amount of CFH hijacked to the bacterial surface, hence the level of complement-mediated bacterial killing and 
an individual's susceptibility to meningococcal disease.
DOI: 10.7554/eLife.04008.012
recombinant CFHR3 reduces the amount of bound CFH in a dose-dependent manner, demonstrating 
antagonism between CFH and CFHR3 for binding to the bacterial surface. When the amount of 
recombinant CFHR3 is added at approximately equimolar levels to those in NHS, the level of CFH 
bound on the bacterial surface is only half that seen in the CFHR3-deficient sera (1–1.6 μM [Fritsche 
et al., 2010]).
In summary, our work demonstrates that susceptibility to an important infectious disease is gov-
erned by the competition between two complement factors with opposing effects (CFH and CFHR3) 
for overlapping binding sites on a single pathogen molecule. Our data predict that the risk of devel-
oping meningococcal disease will be governed by the relative abundance of CFH and CFHR3 in indi-
viduals and the affinity of these molecules for the specific fHbp on the bacterial surface (Figure 6D). It 
is notable that the ΔCFHR3/1 allele has a high prevalence in sub-Saharan Africa (Holmes et al., 2013) 
where there are high rates of epidemic disease. Our mechanism is consistent with this association, 
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since this allele would enhance the interaction between CFH and fHbp and favour pathogen survival. 
This is particularly true as the ΔCFHR3/1 deletion is associated with increased plasma CFH levels, most 
likely due to the loss of a regulatory locus (Ansari et al., 2013; Zhu et al., 2014). However, host poly-
morphisms in CFHR3 might have less impact on strains of bacteria that express fHbp that more selec-
tively bind CFH. Therefore, susceptibility to meningococcal disease will be influenced by polymorphisms 
and copy number variation affecting two host complement factors and by the relative affinity of fHbp 
on an infecting strain for CFH and CFHR3. This illustrates why genetic association studies in infectious 
diseases are likely to be technically challenging since these will be influenced not only by sequence 
and structural variation within the host but also by genetic variation in pathogen.
Materials and methods
Cloning and mutagenesis for protein expression
Sequences encoding CFHR145, CFHR312, CFHR345 and CFHR445 were amplified using primer pairs 
CFHR1-4-Forward(5′-GAAGGAGATATACCATGACGGGAAAATGTGGGCC-3′)/CFHR1-5-Reverse(5′- 
GGCCCACATTTTCCCGTCATGGTATATCTCCTTC-3′), CFHR3-1-Forward(5′-GATATACATATGAAACCT
TGTGATTTTCCAGACATTAAAC-3′)/CFHR3-2-Reverse(5′-GGATCCTCGAGCTAACGGATGCATCTGG
GAGTAG-3′), CFHR3-4-Forward(5′-GGCAGCCATATGTCAGAAAAGTGTGGGCCTCCTC-3′)/CFHR3-5-
Reverse(5′- CGGATCCTCGAGTTATTCGCATCTGGGGTATTCCACTATC-3′) and CFHR3-4-Forward/
CFHR4-5-Reverse(5′- CGGATCCTCGAGTTATTCGCATCTGGGGTATTCCACTATG-3′), respectively. The 
sequence encoding CFHR589 was amplified using primer pair CFHR5-8-Forward(5′-CCACATATGGC 
ATATTGTGGGCCCCCTCCATC-3′)/CFHR5-9-Reverse(5′-GGATCCTCGAGTCATTCACATATAGGATATT
CAAATTTC-3′). Inserts were cloned between the NdeI and XhoI sites of a modified version of 
vector pET-15b (Novagen, Merck Millipore, Billerica, MA), which has the NcoI site replaced with an 
NdeI site.
A vector encoding FH19–20 was generated from that encoding CFHR145 using site-directed muta-
genesis with primers L183S-Forward(5′-GGACAGCCAAACAGAAGCTTTATTCGAGAACAGGTGAA-3′)/
L183S-Reverse(5′-TTCACCTGTTCTCGAATAAAGCTTCTGTTTGGCTGTCC-3′) and A189V-Forward(5′-
TTTGAGAACAGGTGAATCAGTTGAATTTGTGTGTAAACGGG-3 ′ ) /A189V-Reverse (5 ′ - 
CCCGTTTACACACAAATTCAACTGATTCACCTGTTCTCAAA-3′).
The gene encoding full-length CFHR3 was amplified using primers encoding a histidine (His) 
tag (CFHR3-Forward 5′-ATTCGCGGCCGCCCCACCATGTTGTTACTAATCAAT-3′ and CFHR3-Reverse 
5′-CACCATCACCATCACCATTAGCTCGAGGAA-3′) and cloned into a modified version of the pCAGGS 
plasmid (Shimizu et al., 1999) bearing the CMV-EI enhancer, the chicken β-actin promoter, and 
intron 1 of the simian virus 40 poly(A) signal.
The gene encoding full-length CFHR4 was amplified using primer pair CFHR4-Forward(5′- GGA 
CTGTCTAGAGACTCAGATCCCCATCCGCTCAAGCAGGCCACCATGTTGTTACTAATCAA 
TGTCATTCTGACC-3′)/CFHR4-Reverse(5′ GTGTCGGGTCGACCCTTCGCATCTGGGGTATTCCAC-3′) 
prior to ligation into vector pEF-BOS (Mizushima and Nagata, 1990) between the XbaI and SalI sites 
giving a C-terminal hexahistidine tag.
Recombinant protein expression and purification
Recombinant His-tagged fHbp was prepared from a selection of natural variant fHbps and alanine 
substitution mutants of fHbp V1, V2, and V3 as described previously (Johnson et al., 2012). All three 
variant types were represented within 27 natural fHbp variant sequences, numbered according to an 
allele ID code as detailed on the Neisseria Multi Locus Sequence Typing website (http://pubmlst.org/
neisseria/) developed by Keith Jolley and sited at the University of Oxford (Jolley and Maiden, 2010).
CFH67 was prepared as previously described (Prosser et al., 2007). CFH19–20, CFHR145, CFHR345, 
CFHR445, and CFHR589 were expressed in E. coli and refolded from inclusion bodies prior to size exclu-
sion chromatography (Superdex S-75, GE Healthcare, Little Chalfont, UK, buffer 50 mM Tris pH 7.5, 
150 mM NaCl) using the same method previously described for CFHR245 (Goicoechea de Jorge 
et al., 2013). CFHR112 was expressed in Kluyveromyces lactis as previously described (Goicoechea 
de Jorge et al., 2013). CFHR312 was prepared in an identical manner to CFH67 with substitution of 
the final size exclusion chromatography step for purification using heparin affinity (Heparin FF col-
umn, GE Healthcare, buffer A: 50 mM Tris pH 7.5, 10 mM NaCl, buffer B: 50 mM Tris pH7.5, 1 M NaCl, 
elution gradient: 50% over 15 CV).
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Recombinant His-tagged CFHR3 was expressed in HEK293 cells using Lipofectmine 2000 (Invitrogen) 
as per manufacturer's instructions. Recombinant His-tagged CFHR3 supernatant was purified by a 
single affinity chromatography step using a His-Trap HP (GE Healthcare) as per manufacturer's instruc-
tions. The bound protein was eluted with 500 mM Imidazole and then dialysed against 10 mM sodium 
phosphate pH7.8.
CFHR4 was expressed transiently in cell line HEK293S GntI−/− from vector pEF-BOS. Transfection 
was performed using 293Fectin (Life Technologies, Carlsbad, CA) as per the manufacturers instruc-
tions. Cells were cultured in suspension using Freestyle 293 Expression medium (Life Technologies) 
at 37°C with 10% CO2 for 96 hr prior to harvesting the media. CFHR4 was purified from the media 
using a Ni-NTA column (Qiagen) as per the manufacturer’s instructions. Purified protein was dialysed 
into phosphate buffered saline (PBS) prior to use.
Surface plasmon resonance
All surface plasmon resonance measurements were made at 25°C using either a Biacore 3000 
(GE Healthcare) or ProteOn XPR36 (BioRad, Hercules, CA) instrument with buffer HBS-EP (10 mM Hepes 
pH7.4, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant-P20). Proteins were immobilised via primary amine 
coupling with a mock activated–deactivated reference channel included on each. Measurement of the 
affinity between CFHR312 and fHbp V3 was performed by immobilising approximately 1200 RU fHbp on 
the surface of a CM5 sensor chip (GE Healthcare). Dilution series of CFHR312 ranging from 12.5 nM–0.2 nM 
were flowed over the surface at 40 µl/min using KINJECT with a contact time of 300 s and dissocia-
tion time of 1200 s. The surface was regenerated with 10 mM glycine pH 3.0 between each injection. 
Curves were mock subtracted and fit with a 1:1 Langmuir model using BiaEvaluation (GE Healthcare).
Analysis of binding of CFHRs and CFHR fragments to fHbp V3 was performed using a CM5 chip 
with approximately 1700 RU fHbp immobilised. 100 µl of each analyte at a minimum concentration of 
200 nM was flowed over the surface at 20 µl/min using the KINJECT command with a dissociation time 
of 400 s. The surface was regenerated using 10 mM glycine pH 3.0 between injections. Curves were 
mock subtracted using BiaEvaluation.
Measurement of the large panel of fHbp mutants was performed by immobilization of the pro-
teins on ProteOn GLM sensor chips (BioRad). Increasing concentrations of CFHR312 or fH67 were 
injected over the flow channels at 60 µl/min for 240 s and allowed to dissociate for 1200 s. The surface 
was regenerated with 10 mM glycine pH 3.0 between each injection. Curves were mock subtracted 
and fit with a 1:1 Langmuir model using ProteOn manager software (BioRad).
Microscale thermophoresis
fHbp V3 was labelled using the RED-NHS labelling kit (NanoTemper Technologies, Munich, Germany) 
as per the manufacturer’s instructions. Dilution series of CFHR312 in the range of 740 nM–23 pM were 
set up using HBS-EP. Each sample also contained 4 nM labelled fHbp. Thermophoresis was meas-
ured using a Monolith NT.115 instrument (NanoTemper Technologies) at 22°C utilising hydrophilic 
treated capillaries (NanoTemper Technologies), 80% LED power and 60% LED power. All data were 
measured in triplicate across three independent dilution series. Data were analysed using the signal 
from Thermophoresis + T-Jump (NT Analysis software version 1.5.41, NanoTemper Technologies).
Haemolytic assays
The effect of CFHR3, CFHR312, CFHR345, CFHR4, and CFHR445 upon AP activation was assessed 
using haemolytic assays that were performed in an identical manner to that described in Goicoechea 
de Jorge et al. (2013). All measurements were performed in triplicate and are presented as hae-
molysis relative to the level of lysis without addition of CFHR proteins (0%) and 100% lysis by H2O. 
Haemolytic assays with CFH-deficient serum (CompTech, Tyler, TX) were performed with 5% serum.
Bacterial strains and growth
N. meningitidis was grown on brain heart infusion (BHI, Oxoid) agar supplemented with 5% Levinthal's 
base (500 ml defibrinated horse blood autoclaved with 1 l BHI) overnight at 37°C in the presence 
of 5% CO2 (Lucidarme et al., 2009; Jongerius et al., 2013). M1239Δfhbp was constructed as pre-
viously (Jongerius et al., 2013) and isogenic strains were constructed by complementing the strains 
with fHbp V1.P1, V1.P14, V2.P22, or V3.P28 amplified using primers listed in Table 1. Polymerase 
chain reaction products were ligated into pGCC4 (Mehr and Seifert, 1998). Transformation of 
N. meningitidis strain M1239Δfhbp was performed as described previously (Exley et al., 2005).
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Serum survival assay
NHS were obtained by collecting whole venous blood and allowing it to coagulate at room tempera-
ture for 60 min before centrifuging at 3000×g for 20 min at 4°C. Sera were heat inactivated at 56°C 
for 30 min prior to use. N. meningitidis was grown overnight on BHI agar, re-suspended in PBS then 
diluted to 1 × 105 CFU/ml in DMEM (Sigma). A total of 1 × 104 CFU of bacteria were pre-incubated 
with 1 µM CFHR3, 1 µM CFHR3 domains or PBS for 10 min prior to incubation with 5% human sera or 
5% heat inactivated sera for 30 min at 37°C in the presence of CO2. Bacterial survival was deter-
mined by plating onto BHI agar. Relative survival was calculated from samples containing no CFHR3 
and incubated with heat-inactivated sera and expressed as percentage survival.
For the AP assays, bacteria were grown on BHI agar supplemented with 1 mM IPTG. Other com-
plement pathways were inhibited by the addition of 5 mM MgCl2/10 mM EGTA, and bacteria were 
incubated in 25% sera as above. Statistical significance was tested using the one-way ANOVA mul-
tiple comparisons as implemented in GraphPad Prism v.6.0 (GraphPad Software Inc.) to compare 
means ±S.E.M. using a p < 0.01 cutoff for significance.
Monoclonal antibody production
Recombinant CFHR345 conjugated to KLH (Imject, Pierce) was used as an antigen. Female BALB/c mice 
were immunised with 100 μg of recombinant protein emulsified in TitreMax Gold (Sigma, UK) 
subcutaneously on day 1, then with 100 μg of CFHR345 in PBS intraperitoneally (IP) on days 21 and 
42. A booster of 200 μg of recombinant protein in PBS was given IP 3 days prior to cell fusion on 
day 63. NS0 myeloma cells were grown in RPMI 1640 (Lonza, UK) supplemented with 10% foetal 
bovine serum (FBS, Sigma, UK), 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 μg/ml) 
(Galfre and Milstein, 1981). Splenectomy was performed on day 66, and splenocytes fused to 
NS0 myeloma in polyethylene glycol (PEG 1500, Roche, UK) (Mason et al., 1983). Fused cells were 
then plated into 24-well plates in RPMI 1640 containing 2 mM L-glutamine, penicillin (100 U/ml), 
streptomycin (100 μg/ml), and 1% Ultroser G (Pal France). After 24 hr, 2% hypoxanthine adminopterin 
thymidine (HAT, Life technologies) was added to the wells. Hybridoma clone supernatants were 
screened by ELISA against recombinant CFHR345. Positive clones were re-plated and grown for a 
further 5 days before screening again by ELISA against the CFHR345 and all five CFHR proteins. 
Positive hybridoma cells were sub-cultured into 96-well plates at a concentration of 1 cell per well in 
RPMI 1640 containing 10% FBS, 2 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 μg/ml), 
Ultroser G (1%), and BM Condimed H1 (1%, Roche, UK). After 5 days, wells containing single colonies 
were screened as before.
Flow cytometry
Bacteria (1 × 109 CFU/ml) were fixed in 1 ml of 3% formaldehyde for 2 hr then washed with PBS. To 
evaluate CFHR3 binding, 5 × 107 CFU/ml were re-suspended in 10 μl of NHS or 10 µl of sera from an 
individual with ΔCFHR3/1 for 30 min at room temperature. After two washes in 0.05% BSA/PBS, 
Table 1. Primers used to generate bacterial strains
Primer name
Strain  
amplified Ref Primer Sequence (restriction site underlined)
pgcc4V1.1 F H44/76 (Jongerius  
et al., 2013)
CGGTTAATTAAGGAGTAATTTTTGTGAATCGAACTGCCTTCTGCT
pgcc4V1.1 R H44/76 (Jongerius  
et al., 2013)
CGGTTAATTAATTATTGCTTGGCGGC
pgcc4V1.14 F NZ98/254 CGGTTAATTAAGGAGTAATTTTTGTGAACCGAACTGCC
pgcc4V1.14 R NZ98/254 CGGTTAATTAATTATTGCTTGGCGGCAAGAC
pgcc4V2.22F FAM18 CGGTTAATTAAGGAGTAATTTTTGTGAACCGAACTGCCTTCTGCT
pgcc4V2.22R FAM18 CGGTTAATTAACTACTGTTTGCCGGCGATGC
pgcc4V3.28 F M1239 CGGTTAATTAAGGAGTAATTTTTGTGAATCGAACTGCCTTCTGCT
pgcc4V3.28 R M1239 CGGTTAATTAACTACTGTTTGCCGGCGATGC
DOI: 10.7554/eLife.04008.013
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binding was detected following incubation with the anti-CFHR3 mAb (HSL1 this study) for 30 min 
at 4°C in 50 μl of PBS. Cells were washed twice in 0.05% BSA, then resuspended in 50 μl of goat anti-
mouse IgG-Alexa Fluor 647 conjugate (1 in 1000 dilution in PBS; Molecular Probes, Life Technologies) 
and incubated for 30 min at 4°C. Samples were run on a FACSCalibur (BD Biosciences), and at least 
104 events recorded before results were analysed by calculating the geometric mean FL-4 in FlowJo vX 
software (Tree Star).
To evaluate the influence of CFHR3 on CFH binding to bacteria, 5 × 107 CFU/ml of N. meningitidis 
M1239 were incubated in 10 µl of ΔCFHR3/1 sera and twofold dilutions of recombinant full-length 
CFHR3 (from 1 µM) for 30 min at room temperature. CFHR3 binding was detected with the anti-
CFHR3 mAb (HSL1 this study) or an anti-human CFH mAb (MRC OX24, 0.1 μg/ml) (Sim et al., 1983), 
followed by incubating with goat anti-mouse IgG-Alexa Fluor 647 conjugate (1 in 1000 dilution in 
PBS; Molecular Probes, Life Technologies) and analysed by flow cytometry. At least 104 events were 
recorded before results were analysed by calculating the geometric mean FL-4 in FlowJo vX software 
(Tree Star). Maximum fluorescence for CFHR3 was normalised to the addition of 1 µM exogenous 
CFHR3, whereas the maximum fluorescence for CFH was normalised without the addition of exog-
enous CFHR3. Statistical significance was tested using the one-way ANOVA multiple comparisons 
as implemented in GraphPad Prism v.6.0 (GraphPad Software Inc.) to compare means ±S.E.M. using 
a p < 0.01 cutoff for significance.
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